The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal medication development issues for opiate addiction

Neuropsychopharmacology

Volumn 13, Issue 4, 1995, Pages 269-293

  Herman, Barbara H ^a   Vocci, Frank ^a   Bridge, Peter ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Morphine; Nitric oxide; NMDA receptor; Opiate addiction; Tolerance; Withdrawal

Indexed keywords

2 AMINO 4,5 (1,2 CYCLOHEXYL) 7 PHOSPHONOHEPTANOIC ACID; 6,7 DIMETHYL 5 NITRO 2,3 QUINOXALINEDIONE; DECAHYDRO 6 PHOSPHONOMETHYL 3 ISOQUINOLINECARBOXYLIC ACID; DEXTROMETHORPHAN; DIZOCILPINE; KETAMINE; METHYLENE BLUE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; OPIATE; PHENCYCLIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; DRUG TOLERANCE; DRUG WITHDRAWAL; GUINEA PIG; MOUSE; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; RAT; REVIEW;

ANIMALS; ENZYME INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; NARCOTICS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OPIOID-RELATED DISORDERS; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0029562938     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1016/0893-133X(95)00140-9     Document Type: Review

References (166)

1. Aceto, MD, Dewey WL, Chang JK, Lee NM (1982): Dynor-phin (1-13) effects in nontolerant and morphine-dependent rhesus monkeys. Eur J Pharmacol 83:139-142
2. Aceto MD, Dewey WL, Portoghese PS, Takemori AE (1986): Effect of p-funaltrexamine (fl-FNA) on morphine dependence in rats and monkeys. Eur J Pharmacol 123:387-393
3. Aceto MD, Bowman ER, Harris LS (1990): Dependence studies of new compounds in the rhesus monkey, rat and mouse NIDA Res Monogr 95:578-631
4. Aghajanian GK (1978): Tolerance of locus coeruleus neurons to morphine and suppression of withdrawal responses by clonidine. Nature 276:186-188
5. Akaoka H, Aston-Jones G (1991): Opiate-withdrawal-induced hyperactivity of locus coeruleus neurons is substantially mediated by augmented excitatory amino acid input I Neurosci 11:3830-3839
6. Albers GW, Saenz RE, Moses JA, Choi DW (1991): Safety and tolerance of oral dextromethorphan in patients at risk for brain ischemia. Stroke 22:1075-1077
7. Auer RN (1994): Assessing structural changes in the brain to evaluate neurotoxicological effects of NMDA receptor an tagonists. Psychopharmacol Bull 30:585-592
8. Auer RN, Coulter KC (1994): The nature and time course of neuronal vacuolation induced by the NMDA antagonist MK-801. Acta Neuropathol (Berl) 87:1-7
9. Babbedge RC, Bland-Ward PA, Hart SL, Moore PK (1993): Inhibition of rat cerebellar nitgric oxide synthase by 7-nitro indazole and related substituted indazoles. BrJ Pharmacol 110:225-228
10. Babey A-M, Kolesnikov Y, Cheng J, Inturrisi CE, Trifilletti RR, Pasternak GW (1994): Nitric oxide and opioid tolerance. Neuropharmacology 33:1463-1470
11. Ball JC, Ross A (1991): The Effectiveness of Methadone Maintenance Treatment. New York, Springer-Verlag
12. Barjavel M, Bhargava HN (1994): Effect of morphine tolerance and abstinence on nitric oxide synthase activity in brain regions and spinal cord of the mouse. Soc Neurosci 20:1234
13. Baron BM, Kehne JH, Sorensen SM, Harrison BL, Salituro FG, White S (1994): Design and pharmacological evaluation of highly selective glycine antagonists. In Palfrey -man MG, Reynolds, IJ, Skolnick P (eds), Direct and Allosteric Control of Glutamate Receptors. Boca Raton, FI… CRC Press, pp 105-117
14. Ben-Eliyahu S, Marek P, Vaccarino AL, Mogil JS, Sternberg WF, Liebskind JC (1992): The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat. Brain Res 575:304-308
15. Bhargava HN (1978): The effects of naltrexone on the development of physical dependence on morphine. Eur 1 Pharmacol 50:193-202
16. Bhargava HN (1994): Diversity of agents that modify opioid tolerance, physical dependence, abstinence syndrome, and self-administration behaviors. Pharmacol Rev 46: 293-324
17. Bhargava HN (1995a) Attenuation of tolerance to, and physical dependence on, morphine in the rat by inhibition of nitric oxide synthase. Gen Pharmacol 26:1049-1053
18. Bhargava HN (1995b) Non-competitive antagonism of NMDA receptor inhibits tolerance to U50, 499H, a kappa opioid receptor agonist in the rat. Gen Pharmacol 26:1055-1060
19. Bhargava HN, Matwyshyn GA (1993): Dizocilpine (MK-801) blocks the tolerance to the analgesic but not to the hyperthermic effect of morphine in the rat. Pharmacology 47:344-350
20. Bhargava HN, Thorat SN (1994): Effect of dizocilpine (MK-801) on analgesia and tolerance induced by U-50, 488H, a kappa-opioid receptor agonist in the mouse. Brain Res 649:111-116
21. Bhargava HN, Matwyshyn GA, Gerk PM, Bozek PS, Bailey MD, Ko KH, Simko RJ, Thorat SN (1994): Effect of naltrexone pellet implantation on morphine tolerance and physical dependence in the rat. Gen Pharmacol 25:149-155
22. Bhargava HN, Reddy PL, Gudehithlu KP (1995a): Down-regulation of N-methyl-D-aspartate (NMDA) receptors of brain regions and spinal cord of rats treated chronically with morphine. Gen Pharmacol 26:131-136
23. Bhargava HN, Matwyshyn GA, Gudehithlu KP (1995b): Effect of acute and chronic administration of dizocilpine (MK-801) on the analgesic action of U-50, 488H and brain and spinal cord kappa-opioid receptors. FASEB J Abstr 9: A102
24. Boje KM (1994): In vitro and in vivo studies with glycine partial agonists: A novel strategy for preventing NMDA receptor-mediated tissue damage. In Palfreyman MG, Reynolds IJ, Skolnick P (eds), Direct and Allosteric Control of Glutamate Receptors. Boca Raton, FL, CRC Press, pp 119-126
25. Bonuccelli U, Del Dotto P, Piccini P, Behge F, Corsini GU, Muratorio A (1992): Dextromethrophan and parkinsonism [letter]. Lancet 340:53
26. Boulter J, Hollmann M, O'Shea-Greenfield A, Hartley M, Deneris E, Maron C, Heinemann S (1990): Molecular cloning and functional expression of glutamate receptor subunit genes. Science 249:1033-1037
27. Bredt DS, Snyder SH (1992): Nitric oxide, a novel neuronal messenger. Neuron 8:3-11
28. Bredt DS, Huang PM, Snyder SH (1990): Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature 347:768-770
29. Bredt DS, Glatt CE, Huang PM, Fotuhi M, Dawson TM, Snyder SH (1991): Nitric oxide synthase protein and mRNA discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. Neuron 7:615-624
30. Brent PJ, Chahl LA (1993): Enhancement of the opiate withdrawal response by antipsychotic drugs in guinea-pigs is not mediated by sigma binding sites. Eur J Neuropsy-chopharmacol 3:23-32
31. C appendijk SLT, Devries R, Dzolijc MR (1993): Inhibitory effect of nitric oxide (NO) synthase inhibitors on naloxone-precipitated withdrawal syndrome in morphine-dependent mice. Neurosci Lett 162:97-100
32. Choi DW (1988): Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623-634
33. Collingridge GL, Kehl SJ, McLennan H (1983): Excitatory amino acids in synaptic transmission in the schaffer collateral-commissural pathway of the rat hippocampus. J Physiol 334:33-46
34. Culotta E, Koshland DE Jr. (1992): Molecule of the year. NO news is good news. Science 258:1862-1865
35. Curtis DR, Watkins JC (1963): Acidic amino acids with strong excitatory actions on mammalian neurons. J Phvsiol 166:1-14
36. Dawson VL, Dawson TM, London ED, Bredt DS, Synder SI I (1991): Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA 88:6368-6371
37. Dourish CT, Hawley D, Iversen SD (1988): Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist, L-364, 718. Eur J Pharmacol 147:469-472
38. Dourish CT, O'Neill MF, Coughlan J, Kitchener SJ, Hawley D, Iversen SD (1990): The selective CCK-B antagonist L-365, 260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol 176:35 44
39. Dw'yer MA, Bredt DS, Snyder SH (1991): Nitric oxide synthase: Irreversible inhibition by L-NG-nitroarginine in brain in vitro and in vivo. Biochem Res Commun 176 1136-1141
40. Elliott K, Kest B, Inturrisi CE (1995): NMDA receptors, mu and kappa opioid tolerance, and perspectives on new drug development in pain. Neuropsychopharmacology 13: 347-356
41. Elliott K, Hyansky A, Inturrisi CE (1994a): Dextromethorphan attenuates and reverses analgesic tolerance to morphine. Pain 59:361-368
42. Elliott K, Minami N, Kolesnikov YA, Pasternak GW, Inturrisi CE (1994b): The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain 56:69-75
43. Errington ML, Lynch MA, Bliss TV (1987): Long-term potentiation in the dentate gyrus: Induction and increased glutamate release are blocked by D(-)aminophospho-novalerate. Neurosci 20:279-284
44. Fisher RS, Cysyk BJ, Lesser RP, Pontecorvo MJ, Ferkany JI. Swederdt PR, Hart J, Gordon B (1990): Dextromethorphan for treatment of complex partial seizures. Neurology 40:547-549
45. Fix AS (1994): Pathological effects of MK-801 in the rat posterior cingulate/retrosplenial cortex. Psvchophar-macol Bull 30:577-584
46. Fix AS, Horn JW, Wightman KA, Johnson CA, Long GG, Starts RW, Farber N, Wozniak DF, Olney JW (1993): Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): A light and electron microscopic evaluation of the rat retrosplenial cortex. Exp Neurol 123:204-215
47. Foster AC, Kemp JA (1988): HA-966 antagonizes N-methyl-D-aspartate receptors through a selective interaction with the glycine modulatory site. J Neurosci 9:2191-2196
48. Garthwaite J (1991): Glutamate, nitric oxide and cell-cell signalling in the nervous system. TINS 14:60-67
49. Garthwaite J, Charles SL, Chess-Williams R (1988): Endothelium-derived relaxing factor release on activation ot NMDA receptors suggests role as intercellular messenger in the brain. Nature 336:385-388
50. Garthwaite J, Southam E, Anderton M (1989): A kainate receptor linked to nitric oxide synthesis from arginine. J Neu-rochem 53:1952-1954
51. Gronbladh L, Ohlund LS, Gunne LM (1990): Mortality in heroin addiction: Impact of methadone treatment. Acta Psychiatr Scand 82:223-227
52. Grotta J (1994): Safety and tolerance of the glutamate antagonist CGS 19755 in acute stroke patients. Stroke 25:255
53. Gudehithlu KP, Reddy PL, Bhargava HN (1993): Effect of chronic morphine treatment on the binding of 3H-MK801 to rat brain and spinal cord membranes. Pharmacologist 35: A190
54. Gudehithlu KP, Reddy PL, Bhargava HN (1994): Effect of morphine tolerance and abstinence on the binding of 3H-MK801 to rat brain regions and spinal cord of the rat. Brain Res 639:269-274
55. Gutstein HB, Trujillo KA (1993): MK-801 inhibits the development of morphine tolerance at spinal sites. Brain Res 626:332-334
56. Haigler EfJ (1994): NMDA receptor antagonists: Neurotoxicity evaluation. Psychopharmacol Bull 30:525
57. Harris EW, Cotman CW (1986): Long-term potentiation of guinea pig mossy fiber responses is not blocked by N-methyl-D-aspartate antagonists. Neurosci Lett 70: 132-137
58. Herman BH, Vocci F, Majewska D, BridgeP(1993): Development of glutamatergic antagonists: New treatments for opiate addiction. NIDA Research Monograph 141, Vol 2, Problems of Drug Dependence: Proceeding of the 55th Annual Scientific Meeting, College on Problems of Drug Dependence, Inc., Toronto, Canada, June 16, p 472
59. Herrling PL (1994): D-CPPene (SDZ EAA 494), A competitive NMDA antagonist: Results from animal models and first results in humans. Neuropsychopharmacology 10(3): 591
60. Hollmann M, Heinemann S (1994): Cloned glutamate receptors. Ann Rev Neurosci 17:31-108
61. Hollmann M, O'Shea-Greenfield A, Rogers SW, Heinemann S (1989): Cloning by functional expression of a member of the glutamate receptor family. Nature 342:643-648
62. Hood WF, Compton RP, Monahan JB (1989): A ligand for the N-methyl-d-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett 98:91-95
63. Hood WF, Compton RP, Monahan JB (1990): N-methyl-D-aspartate recognition site ligands modulate activity at the coupled glycine recognition site. J Neurochem 54:1040-1046
64. Hood WF, Gray NM, Dappen MS, Watson GB, Compton RP, Cordi AA, Lanthorn TH, Monahan JB (1992): Characterization of indole-2-carboxylate derivatives as antagonists of N-methyl-D-aspartate receptor activity at the associated glycine recognition site. J Pharmacol Exp Ther 262:654-660
65. Huettner JE (1989): Indole-2-carboxylic acid: A competitive antagonist of potentiation by glycine at the NMDA receptor. Science 243:1611-1613
66. Jaffe DB, Marks SS, Greenberg DA (1989): Antagonist drug selectivity for isoligand binding sites on voltage-gated and N-methyl-D-aspartate receptor-gated Ca3+ channels. Neurosci Lett 105:227-232.
67. Jaffe JH (1994): Drug addition and drug abuse. In Goodman Gilman A, Rail TW, Nies AS, Taylor P (eds), The Pharmacological Basis of Therapeutics, ed 8, New York, McGraw-Hill, pp 522-573
68. Jaffe JH, Martin WR (1994): Opioid analgesics and antagonists. In Goodman Gilman A, Rail TW, Nies AS, Taylor P (eds), The Pharmacological Basis of Therapeutics, ed 8, New York, McGraw-Hill, pp 485-521
69. Johnson JW, Ascher P (1987): Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325:529-531
70. Johnson RE, Jaffe JH, Fudala PJ (1992): A controlled trial of buprenorphine treatment for opioid dependence. JAMA 267:2750-2755
71. Kimes A, Vaupel DB, Bruckner M, London E (1991): Nitroar-ginine, a nitric oxide synthase inhibitor, attenuates morphine withdrawal. Soc Neurosci Abst 17:538
72. Kimes AS, Vaupel DB, London ED (1993): Attenuation of some signs of opioid withdrawal by inhibitors of nitric oxide synthase. Psychopharmacology 112:521-524
73. Koek W, Colpaert FC (1990): Selective blockade of N-methyl-D-aspartate (NMD A)-induced convulsions by NMDA antagonists and putative glycine antagonists: Relationship with phencyclidine-like behavioral effects. J Pharmacol Exp Ther 252:349-357
74. Kolesnikov YA, Pick CG, Pasternak GW (1992): Nc:-nitro-L-argine prevents morphine tolerance. Eur J Pharmacol 221: 399-400
75. Kolesnikov YA, Ferkany J, Pasternak GW (1993a): Blockade of mu and kappai opioid analgesic tolerance by NPC17742, a novel NMDA antagonist. Life Sci 53: 1489-1494
76. Kolesnikov YA, Pick CG, Ciszewska G, Pasternak GW (1993b): Blockade of tolerance to morphine but not to kappa opioids by a nitric oxide svnthase inhibitor. Proc Natl Acad Sci U S A 90:5162-5166
77. Kolesnikov YA, Maccechini M-L, Pasternak GW (1994): I-Aminocyclopropate carbolyxic acid (ACPC) prevents mu and delta opioid tolerance. Life Sci 55:1393-1398
78. Kosten TR, DeCaprio JL, Rosen Ml (1995): The severity of naloxone precipitated opiate withdrawal is attenuated by felbamate, a possible glycine antagonist. Neuropsychopharmacology 13:323-333
79. Koyuncuoglu M, Gungor M, Sagduyu II, Aricioglu F (1990) Suppression by ketamine and dextromethorphan of precipitated abstinence syndrome in rats. Pharmacol Bio-chem Behav 35:829-832
80. Koyuncuoglu M, Saydam B (1990): The treatment of heroin addicts with dextromethorphan: A double-blind comparison of dextromethorphan with chlorpromazine. Int J Clin Pharmacol Therapy Toxicol 28:147-152
81. Kristensen JD, Svensson B, Gordh T Jr., (1992): The NMDA-receptor antagonist CPP abolishes neurogenic “wind-up pain" after intrathecal administration in humans. Pain 51:249-253
82. Lambert LE, Whitten JP, Baron BM, Cheng HC, Doherty NS, MacDonald IA (1991): Nitric oxide synthesis in the CNS endothelium and macrophages differs in its sensitivity to inhibition by arginine analogues. Life Sci 48:69-75
83. Leber P (1994): Introduction, Psychotherapeutic Medications Development Program workshop on NMDA receptor an tagonists: Neurotoxicity evaluation. Psvchopharmacol Bull 30:527-532
84. Ling W, Charuvastra VC, Kaim SC, Kleet CJ (1976): Methadyl acetate and methadone as maintenance treatments for heroin addicts. Arch Gen Psychiatr 33:709-720
85. Lufty K, Hurlbut DE, Weber E (1993): Blockade of morphine-induced analgesia and tolerance in mice. Brain Res 616:83-88
86. Lufty K, Shen K-Z, Kwon I-S, Cai SX, Woodward RM, Keana JFW, Weber E (1995): Blockade of morphine tolerance by ACEA-1328, a novel NMDA receptor/glycine site antagonist. Eur J Pharmacol 273:187-189
87. Mao J, Price DD, Mayer DJ, Lu J, Hayes RL (1992): Intrathecal MK-801 and local nerve anesthesia synergistically reduce nociceptive behaviors in rats with experimental peripheral mononeuropathy. Brain Res 576:254-262
88. Mao J, Price DD, Mayer DJ (1994): Thermal hyperalgesia in association with the development of morphine tolerance in rats: Roles of excitatory amino acid receptors and protein kinase C. J Neurosci 14:2301-2312
89. Marek P, Ben-Eliyahu S, Vaccarino AL, Liebskind JC (1991a): Delayed application of MK-801 attenuates morphine tolerance in the rat. Brain Res 558:163-165
90. Marek P, Ben-Eliyahu S, Gold M, Liebskind JC (1991b): Excitatory amino acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res 547:77-81
91. Martin W, Gillespie JS (1990): L-arginine-derived nitric oxide: The basis of inhibitory transmission in the anococ-cygeous and retractor penis muscles. In Bell C (ed), Novel Peripheral Neurotransmitters, New York, Pergamon Press, pp 65-79
92. Marquis KL, Piesla MJ, Muth EA, Boast CA (1991): Effects of acute/chronic MK-801 on naloxone-precipitated jumping in morphine-dependent mice. Soc Neurosci Abst 17:331
93. Marvizon J-CG, Lewin AH, Skolnick P (1989): I-Amino-cyclopropane carboxylic acid: A potent and selective ligand for the glycine modulatory site of the N-methyl-D-aspartate receptor complex. J Neurochem 52:992-994
94. Matwyshyn GA, Bhargava HN (1995): Effect of LY235959, a competitive antagonist of NMDA receptor, on tolerance to and physical dependence on morphine in mice. FASEB I Abstr 9:A102
95. Matswyshun GA, Thorat SN, Barjavel M, Gudehithlu KP, Bhargava HN (1993): Comparative effects of MK-801 and Nt,-monomethyl-L-arginine (NMMA) on morphine abstinence syndrome. Soc Neurosci Abstr 19:1461
96. Mayer DJ (1995): The role of protein kinase C in opiate tolerance, dependence and neuropathic pain. Paper presented at the NIDA Technical Review: The role of glutamater-gic systems in the development of opiate addiction, October 17-18, 1995, Gaithersburg, MD
97. Meldrum BS (1994): Neuroprotection by NMDA and non-NMDA glutamate antagonists. In Palfreyman MG, Reynolds IJ, Skolnick P (eds), Direct and allosteric control of glutamate receptors. Boca Raton, FL, CRC Press, 127-138
98. Moore, PK, Babbedge RC, Wallace P, Gaffen ZA, Hart SL (1993b): Characterization of the novel nitric oxide synthase inhibitor 7-nitro indazole and related indazoles: Antinociceptive and cardiovascular effects. Br J Pharmacol 110:219-224
99. Moore PK, Babbedge RC, Wallace P, Gaffen ZA, Hart SL (IW): 7-Nitro indazole, an inhibitor of nitric oxide synthase, exhibits anti-nonciceptive activity in the mouse without increasing blood pressure. Br J Pharmacol 108:296-297
100. Moriyoshi K, Masu M, Ishii T, Shigemoto R, Mizuno N, Nakanishi S (1991): Molecular cloning and characterization of the rat NMDA receptor. Nature 354:31-37
101. Morris RG, Anderson E, Lynch GS, Baudry M (1986): Selective impariment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 319:774-776
102. Mushlin BE, Cochin J (1976): Tolerance to morphine in the rat: Its prevention by naloxone. Life Sci 18:797-802
103. Netzer R, Pflimlin P, Trube G (1993): Dextromethorphan blocks N-methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons. Eur J Pharmacol 238:209-216
104. Olney JW (1969): Brain lesions, obesity and other disturbances in mice treated with monosodium glutamate. Science 164:719-721
105. Olney JW (1971): Glutamate-induced neuronal necrosis in the infant mouse hypothalamus: An electron microscopic study. J Neuropathol Exp Neurol 30:75-90
106. Olney JW (1991) Excitotoxicity and neuropsychiatric disorders. In AscherP, ChoiDW, Christen Y (eds.), Glutamate, Cell Death and Memory, Heidelberg, Springer-Verlag, pp 77-101
107. Olney JW (1994): The neurotoxicity of NMDA receptor antagonists: An overview. Psychopharmacol Bull 30:533-540
108. Olney JW, Faber N (1995): NMDA antagonists as neurother-apeutic drugs, psychotogens. neurotoxins and research tools for studying schizophrenia. Neuropsvchopharma-cology 13:335-345
109. Olney JW, Sharpe LG, Geigin RD (1972): Glutamate-induced brain damage in infant primates. J Neuropathol Exp Neurol 31:464-488
110. Olney JW, deGubareff T, Labruyere J (1979): a-Aminoadipate blocks the neurotoxic action of N-methylaspartate. Life Sci 25:537-540
111. Olney JW, Farber N (1995): NMDA antagonists as neurothera-peutic drugs, psychotogens, neurotoxins and research tools for studying schizophrenia. Neuropsvchopharma-cology 13:335-345
112. Olney JW, Labruyere J, Collins JF, Curry K (1981): Damino-phosphonovalerate is 100-fold more powerful than D-alpha-aminoadipate in blocking N-methylaspartate neurotoxicity. Brain Res 221:207-210
113. Olney JW, Labruyere J, Price MT (1989): Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244: 1360-1362
114. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA (1991): NMDA antagonist neurotoxicity: Mechanism and prevention. Science 254:1515-1518
115. O'Neill MF, Dourish CT, Iversen SD (1989): Morphine-induced analgesia in the rat paw pressure test is blocked by CCK and enhanced by the CCK antagonist MK-329. Neuropharmacology 28:243-247
116. Ornstein PL, Arnold MB, Augenstein NK, Schoepp DD, Leander JD, Lodge D (1990): The discovery of LY274614 and LY233536 and their characterization as selective and competitive NMDA antagonists Soc Neurosci Abstr 16:858
117. Palfreyman MG (1994): Glutamate receptors and their regulators-an overview. In Palfreyman MG, Reynolds IJ, Skolnick P (eds), Direct and Allosteric Control of Glutamate Receptors, Boca Raton, FL, CRC Press, pp 1-19
118. Pasternak GW, Kolesnikov YA, Babey AM (1995): Perspectives on the NMDA/NO cascade and opioid tolerance. Neuropsychopharmacology 13:309-313
119. Psychotherapeutic medications development program (PMDP) workshop on NMDA receptor antagonists: Neurotoxicity evaluation. Psychopharmacol Bull 30:523-621
120. Pulvirenti L, Swerdlow NR, Koob GF (1991): Nucleus accum-bens NMDA antagonist decreases locomotor activity produced by cocaine, heroin or accumbens dopamine, but not caffeine. Pharmacol Biochem Behav 40:841-845
121. Pulvirenti L, Maldonado-Lopez R, Koob GF (1992) NMDA receptors in the nucleus accumbens modulate intravenous cocaine but not heroin self-administration in the rat. Brain Res 594:327-330
122. Rasmussen K (1995): The role of the locus coeruleus and NMDA and AMPA receptors in opiate withdrawal. Neuropsychopharmacology 13:295-300
123. Rasmussen K, Aghajanian GK (1989): Withdrawal-induced activation of locus coeruleus neurons in opiate-dependent rats: Attenuation by lesion of the nucleus paragigantocel-lularis. Brain Res 505:346-350
124. Rasmussen K, Beitner-Johnson DB, Krstal JH, Aghajanian GK, Nestler EJ (1990): Opiate withdrawal and rat locus coeruleus: Behavioral, electrophysiological, and biochemical correlates. J Neurosci 10:2308-2317
125. Rasmussen K, Fuller RW, Stockton ME, Perry KW, Swinford RM, Ornstein PL (1991): NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal. Eur J Pharmacol 197:9-16
126. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S (1990): Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 101:746-752
127. Reich DL, Silvay G (1989): Ketamine: An update on the first twenty years of clinical experience. Can J Anaesth 36:186-197
128. Rice DP, Kelman S, Miller LS (1991): Economic costs of drug abuse, NIDA Research Monograph 113: Economic Costs, Cost-Effectiveness, Financing, and Community-Based Drug Treatment, pp NIDA, 10-32
129. Rosen MI, McMahon TH, Woods S, Pearsall HR, Kosten TR (1995): The effect of dextromethorphan on naloxone-precipitated opiate withdrawal. Paper presented at the NIDA Technical Review: The role of glutamatergic systems in the development of opiate addiction, October 17-18, Gaithersburg, MD
130. Saenz R, Tanner CM, Albers G, Kurth M, Tetrud J (1993): A preliminary study of dextromethorphan (DM) as adjunctive therapy in Parkinson's Disease (PD). Neurology 43:A155
131. Scatton B, Avenet P, Benavides J, Carter C, Duverger D, Ob-lin A, Perrault G, Sanger DJ, Shoemaker H (1994): Neu-roprotective potential of the polyamine site-directed NMDA receptor antagonists—ifenprodil and eliprodil. In Palfreyman MG, Reynolds IJ, Skolnick P (eds), Direct and Allosteric Control of Glutamate Receptors, Boca Raton, FL, CRC Press, pp 139-154
132. Schoepp DD, Ornstein PL, Salhoff CR, Leander JD (1991): Neuroprotectant effects of LY274614, a structurally novel systemically active competitive NMDA receptor antagonist. J Neural Transm 85:133-143
133. Singh L, Menzies R, Tricklebank MD (1990): The discriminative stimulus properties of (+)-HA-966, an antagonist at the glycine/N-methyl-D-aspartate receptor. EurJ Pharmacol 186:129-132
134. Smits EE (1976): Antagonism by naloxone of morphine-induced single-dose dependence and antinociception in mice. Res Commun Chem Path Pharmacol 15:689-696
135. Snyder SH, Bredt S (1991): Nitric oxide as a neuronal messenger. Trends Pharmacol Sci 12:125-128
136. Sommer B, Seeburg PH (1992): Glutamate receptor channels—novel properties and new clones Trends Pharmacol Sci 13:291-296
137. Sugiyama H, Ito I, Hiron C (1987): A new type of glutamate receptor linked to inositol phospholipid metabolism. Nature 325:531-533
138. Szekely JI (1994): Opioid Peptides m Substance Abuse. Boca Raton, FL, CRC Press
139. Takemori AE, Loh HH, Lee NM (1992): Supression by dv-norphin A (1-13) of the expression of opioid withdrawal and tolerance in mice. Eur J Pharmacol 221:223-226
140. Takemori AE, Loh HH, Lee NM (1993): Suppression by Dv-norphin A and [Des-Tyr1] Dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice. J Pharmacol Exp Ther 266:121-124
141. Tanganelli S, Antonelli T, Morari M, Bianchi C, Beani L (1991): Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs. Neurosci Lett 122:270-272
142. Thorat SN, Bhargava HN (1995): Competitive antagonism of NMDA receptor inhibits the development of tolerance to a kappa-opioid receptor agonist in mice. FASEB J Abstr 9:A102
143. Thorat SN, Reddy PL, Bhargava HN (1993): Evidence for the role of nitric oxide in kappa-opioid tolerance in mice. Brain Res 621:171-174
144. Thorat SN, Barjavel M, Matwyshyn GA, Bhargava HN (1994): Comparative effects of N(,-monomethyl-L-arginine and MK-801) on the abstinence syndrome in morphine-dependent mice. Brain Res 642:153-159
145. Tiseo PJ, Inturrisi CE (1993): Attenuation and reversal of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist, LY274614. J Pharmacol Exp Ther 264:1090-1096
146. Tiseo PJ, Cheng J, Pasternak GW, Inturnsi CE (1994): Modulation of morphine tolerance by the competitive N-Meth-yl-D-Aspartate receptor antagonist LY274614: Assessment of Opioid Receptor Changes. J Pharmacol Exp Ther 268:195-201
147. Tremblay E, Colombel MC, Jacob J (1976): Precipitation et prevention de Tabstinence chez le rat et la souris en etat de dependence aigue: comparison de la diprenorphine. Psychopharmacology 49:41-48
148. Trujillo KA (1995): Effects of noncompetitive N-methyl-D-aspartate receptor antagonists on opiate tolerance and physical dependence. Neuropsychopharmacology 13: 301-307
149. Trujillo KA, Akil H (1991a): Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251:85-87
150. Trujillo KA, Akil H (1991b): The NMDA receptor antagonist MK-801 increases morphine catalepsy and lethality. Pharmacol Biochem Behav 38:673-675
151. Trujillo KA and Akil H (1994): Inhibition of opiate tolerance by non-competitive N-methyl-D-aspartate receptor antagonists. Brian Res 633:178-188
152. Trullas R, Folio T, Young A, Miller R, Boje K, Skolnick P (1991): I-Aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models. Eur J Pharmacol 203:379-385
153. Tulnay FC, Jen M-F, Chang J-K, Loh HH, Lee NM (1981): Possible regulatory role of dynorphin on morphine-and B-endorphin-induced analgesia. J Pharmacol Exp Ther 219:296-298
154. Y'aupel DB, Kimes AS, London ED (1995): Comparison of 7-nitroindazole w'ith other nitric oxide synthase inhibitors as attenuators of opioid withdrawal. Psychopharmacology 118:361-368
155. Vaupel DB, Kimes AS, London ED (1995): Nitric oxide synthase inhibitors: preclinical studies of potential use for treatment of opiate addiction. Neuropsychopharmacology 13:315-322
156. Watkins JC (1978): Excitatory amino acids. In McGeer E, Ol-ney JW, McGeer P (eds), Kainic Acid as a Tool in Neurobiology, New' York, Raven, pp 37-69
157. Watkins JC, Evans RH (1981): Excitatory amino acid transmitters. Ann Rev Pharmacol Toxicol 21:166-210
158. Watkins L, Kinschenck IB, Mayer DJ (1984): Potentiation of morphine analgesia and apparent reversal of morphine tolerance by proglumide. Science 224:395-396
159. Watson GB, Lanthorn TH (1990): Pharmacological characteristics of cyclic homologues of glycine at the N-methyl-D-aspartate receptor-associated glycine site. Neurophar-macol 29:727-730
160. Willetts J, Balster RL, Leander JD (1990): The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci 11:423-428
161. Williams K, Romano C, Dichter MA, Molinoff PB (1991): Minireview. Modulation of the NMDA receptor by polyamines. Life Sci 48:469-498
162. Wong EHF, Kemp JA (1991): Sites for antagonism on the N-methyl-D-aspartate receptor channel complex. Annu Rev Pharmacol Toxicol 31:401-425
163. Xie CW, Lewis DV (1991): Opioid-mediated facilitation of longterm potentiation at the lateral perforant path-dentate granule cell synapse. J Pharmacol Exp Ther 256:289-296
164. Xie Q, Cho HJ, Calaycay J, Mumford RA, Swidereck KM, Lee TD, Ding A, Troso T, Nathans C (1992): Science 256: 225-228
165. Yano 1, Takemori AE (1977): Inhibition by naloxone of tolerance and dependence in mice treated acutely and chronically with morphine. Res Commun Chem Pathol Pharmacol 16:721-734
166. Zvsset T, Fengin T, Kupfer A (1988): In-vivo and in vitro dextromethorphan metabolism in SD and DA rat: An animal model of the debrisoquine-type polymorphic oxidation in man. Biochem Pharmacol 37:3155-3160